BMTI Insider Trading Activity and SEC Form 4 Filings
BMTI insider trading summary
No open-market insider purchases or sales of Biomimetic Therapeutics, Inc. (BMTI) have been reported on SEC Form 4 in the past 12 months.
Latest BMTI insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Jan 22, 2013 | Russell P. Pagano | VP, Reg. & Clinical Affairs | Sell | $11K (1,381 @ $8.10) |
| Apr 2, 2012 | Gary E Friedlaender | Director | Buy | $28K (10,000 @ $2.79) |
| Mar 30, 2012 | Samuel Eugene Lynch | President and CEO | Buy | $48K (20,000 @ $2.40) |
| Mar 30, 2012 | Samuel Eugene Lynch | President and CEO | Buy | $48K (19,362 @ $2.46) |
| Mar 29, 2012 | Samuel Eugene Lynch | President and CEO | Buy | $73K (30,638 @ $2.38) |
| Mar 29, 2012 | Russell P. Pagano | VP, Reg. & Clinical Affairs | Sell | $8K (3,438 @ $2.36) |
| Mar 28, 2012 | Earl Martin Douglas | General Counsel | Sell | $12K (5,000 @ $2.36) |
| Mar 28, 2012 | Earl Martin Douglas | General Counsel | Sell | $3K (1,100 @ $2.32) |
| Mar 28, 2012 | Earl Martin Douglas | General Counsel | Sell | $7K (3,000 @ $2.34) |
| Mar 28, 2012 | Earl Martin Douglas | General Counsel | Sell | $3K (1,400 @ $2.33) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.